Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to Medicaid "redetermination" processes and that premium rates were sufficient to cover rising costs [4]. - Contrary to these claims, the redetermination process led to a significant increase in Medicaid member utilization, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - Following a Q3 2024 earnings report on October 17, 2024, where Elevance missed EPS expectations by $1.33 (13.7%) due to elevated medical costs, the company lowered its EPS guidance for 2024 from $37.20 to $33.00 (11.3%), causing the stock price to decline by $52.61 per share, or 10.6%, to a closing price of $444.35 [7][8].

Key Takeaways Globe Life shares have gained 41.5% in the past year compared with the industry's growth of 24.2%. GL targets a 300% to 320% consolidated RBC ratio for 2025, supporting financial strength. The American Income and Liberty National divisions are expected to fuel future top-line growth.Globe Life Inc. (GL) shares are trading at a discount compared with the Zacks Accident and Health Insurance industry. Its forward price-to-earnings multiple of 8.22X is lower than the industry average of 12.27X, ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Financial Implications - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process and believed their negotiated rates were adequate [4]. - However, the redetermination process resulted in a significant increase in the acuity and utilization of Medicaid members, which was not reflected in Elevance's financial guidance for 2024 [5]. Group 4: Stock Performance - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further decline in stock price by $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

If you're an income-seeking investor, a buoyant stock market near its all-time high is actually a problem. At recent prices, the average stock in the benchmark S&P 500 index offers an itty-bitty 1.2% dividend yield.A low average dividend yield suggests the market is overbought, but that doesn't mean there aren't any hidden gems out there. UnitedHealth Group (UNH) and Prologis (PLD) have been flying under the radar even though they both offer yields that are more than double the benchmark average.UnitedHealt ...

Core Insights - The Big Beautiful Bill Act (BBBA) is projected to cut $1 trillion from Medicaid, which constitutes 62% of Centene's 2024 revenue [2][4] - Centene's stock experienced a 40% decline following the withdrawal of its 2025 revenue guidance due to an independent actuary's report indicating overly optimistic revenue assumptions [2][3] - S&P Global Ratings is contemplating downgrading Centene's credit rating to junk status, which could increase the company's cost of capital [4][14] Financial Performance - Centene's revenue from Medicaid was $101.4 billion, representing 62% of total revenue for 2024, while Medicare contributed 14% and the Commercial Marketplace business unit accounted for 21% [7] - In Q1 2025, Centene reported a 15.4% increase in revenue to $46.6 billion, exceeding analyst expectations [16] - The company’s adjusted earnings per share (EPS) for Q1 2025 was $2.90, which was 22.9% higher than consensus estimates [16] Market Impact - The BBBA's Medicaid cuts could reduce Centene's revenue growth rate by one percentage point annually over the next five years, from 5% to 4% [13] - Analysts have expressed concerns about the potential for Centene's EPS forecast to be significantly lowered, with estimates suggesting a possible reduction of $2.75 [11][12] - Despite the negative outlook, some analysts believe Centene is significantly undervalued, with a 12-month price target averaging $63.08, indicating a potential upside of nearly 91% [20] Strategic Concerns - The withdrawal of revenue guidance has raised questions about Centene's future profitability and capital adequacy, leading to increased scrutiny from credit rating agencies [15] - The company faces challenges in offsetting potential revenue losses from Medicaid cuts with other business lines [8] - The healthcare sector, particularly managed care, is viewed as increasingly risky by some analysts, with concerns that conditions may worsen before improving [19]

PHILADELPHIA, July 08, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations of Misrepresentation - Elevance claimed to be closely monitoring cost trends related to the Medicaid redetermination process and asserted that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - On July 17, 2024, Elevance announced an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, which revealed a miss in EPS expectations by $1.33 (13.7%) due to elevated medical costs, the stock price fell by $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

PHILADELPHIA, July 7, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repre ...

SAN FRANCISCO, July 7, 2025 /PRNewswire/ -- On July 2, 2025, investors in Centene Corp. (NYSE: CNC) saw the price of their shares of this normally low-volatility stock crash 40%, after the company withdrew its guidance, blaming preliminary discussions and data generated by an independent actuary, Wakely.The unusual circumstances and severe investor reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Centene may have violated the securities laws. The fi ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...